These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 22193561

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
    Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A.
    Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
    [Abstract] [Full Text] [Related]

  • 4. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L, European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [Abstract] [Full Text] [Related]

  • 5. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
    Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, Investigators of the 16-year Long-Term Follow-Up Study.
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
    Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH, Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.
    Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
    [Abstract] [Full Text] [Related]

  • 9. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG.
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 14. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [Abstract] [Full Text] [Related]

  • 15. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 16. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.
    Uher T, Benedict RH, Horakova D, Bergsland N, Dusankova JB, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.
    J Neurol Sci; 2014 Dec 15; 347(1-2):229-34. PubMed ID: 25456460
    [Abstract] [Full Text] [Related]

  • 17. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
    Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, 16-Year Long-Term Follow-up Study Investigators.
    PLoS One; 2011 Dec 15; 6(11):e22444. PubMed ID: 22140424
    [Abstract] [Full Text] [Related]

  • 18. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 19. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
    Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V.
    J Neurol Sci; 2006 Jun 15; 245(1-2):141-5. PubMed ID: 16626758
    [Abstract] [Full Text] [Related]

  • 20. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
    Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study.
    Neurology; 2010 Jun 08; 74(23):1877-85. PubMed ID: 20530324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.